JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid Leukemia Treated with Imatinib.
Indra WijayaMuhammad H BashariLelani ReniartiAnita RahmawatiRully M A RoesliPublished in: Disease markers (2024)
Based on these findings, JAK2 levels may be a potential indicator for evaluating treatment response on imatinib due to its role in the pathophysiology of CML.